MedTrace Logo

Idiopathic Parkinson's Progression and Dopamine Transporter SPECT

NCT03531086 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2022-11-17

No results posted yet for this study

Summary

DaTscanTM Ioflupane I123, a radiopharmaceutical will be used as an adjunct diagnostic tool in combination with single photon emission computed tomography (SPECT) to evaluate striatal dopamine transporter (DAT) distribution in patients with idiopathic Parkinson's disease. Patients will be monitored twice - once at baseline, and again after 1 year - to identify potential biomarkers for progression of Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

Ioflupane I 123

Ioflupane I 123 will be administered IV push prior to SPECT imaging

Sponsors & Collaborators

  • Julie Gurwell

    lead OTHER

Principal Investigators

  • Julie Gurwell, PhD, PA-C · University of Kentucky

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-19
Primary Completion
2021-09-01
Completion
2021-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03531086 on ClinicalTrials.gov